A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)

Trial Profile

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs SR T100 (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms GESRTAKB
  • Sponsors G&E Herbal Biotechnology
  • Most Recent Events

    • 01 Jun 2017 Planned number of patients changed from 106 to 86.
    • 01 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top